PD173955
PD173955 is an orally active inhibitor of Src (IC50= 22 nM), Yes, Abl, ATP and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity[1][2][3][4].
Product Specifications
CAS Number
260415-63-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Bcr-Abl; Src
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PD173955.html
Purity
99.12
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=CC(SC)=C4)N=C3N1C
Molecular Formula
C21H16Cl2N4OS
Molecular Weight
443.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Moasser MM, et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15;59 (24) :6145-52. PMID: 10626805.|[2]Martinelli G, et al. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2005 Nov;19 (11) :1872-9. |[3]Netzer WJ, et al. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proc Natl Acad Sci U S A. 2017 Feb 7;114 (6) :1389-1394. |[4]Wolff NC, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 May 15;105 (10) :3995-4003.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![p21 Mouse Monoclonal Antibody [A8C11]](https://cdn.genprice.uk/products/992/68dd1c90061270361ea82b33/imageurl/ha601018.webp)
BNC040639-500 1x 500 µL
CD31 / PECAM-1 (JC/70A), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details